Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude
Research
[키워드] all ethnic groups
alpha-2b
analysed
Analysis
antiviral agent
approach
Biomarker
calculated
ceftriaxone
Characteristics
Chloroquine
clinical
Clinical practice
clinical trial
Colchicine
collected
Comorbidities
comprehensive analysis
Coronavirus disease 2019
COVID-19
COVID-19 patient
daclatasvir
defined
Dexamethasone
drug
Drug efficacy
Drug score
drug therapy
Drug-to-drug interaction
drugs
ethnic group
Ethnicity-based differences
evaluate
facilitate
Frequency
functional
Future healthcare
Gene score
generate
genetic difference
genetic differences
genetic test
HCQ
highest
human immunoglobulin
human immunoglobulin G
Hydroxychloroquine
immune regulator
indicated
Individual outcomes
individuals
interferon
interferon alpha-2b
Interferon beta-1a
levofloxacin
Lopinavir
losartan
management
molecular mechanisms
Optimal medication
patients with comorbidity
performed
Personalized medicine
personalized treatment
pharmacogenetic
pharmacogenetics
pharmacogenomics
Predictive
Predictive preventive personalized medicine (PPPM/3 PM)
Prednisone
Remdesivir
reported
Result
ribavirin
Ritonavir
significantly
sofosbuvir
suggested
supplementary material
the patient
translation
Treatment
Trial
Variation
variations
Zinc
[DOI] 10.1007/s13167-021-00247-0 PMC 바로가기 [Article Type] Research
[DOI] 10.1007/s13167-021-00247-0 PMC 바로가기 [Article Type] Research